RESUMEN
Mutations in MYD88 cause susceptibility to invasive bacterial infections through impaired signaling downstream of toll-like receptors (TLRs) and IL-1 receptors. We studied a patient presenting with neutropenia, delayed umbilical cord separation, BCG adenitis, andP. aeruginosapneumonia. Next-generation DNA sequencing identified a novel homozygous truncation mutation in MYD88 that abolishes MyD88 expression. The patient's dermal fibroblasts had severely impaired IL-6 production after stimulation with ligands for the MyD88-dependent receptors TLR2, TLR4 and IL-1R, while responses to ligands for the MyD88-independent receptors TLR3 and TNF-α were preserved. Notably, secretion of TNF-α, which is essential for BCG control, was also impaired after LPS stimulation. In this first report of BCG infection in MyD88 deficiency, data suggest that MyD88-dependent TNF-α production contributes to control of mycobacterial disease.
Asunto(s)
Vacuna BCG/efectos adversos , Linfadenitis/patología , Factor 88 de Diferenciación Mieloide/genética , Neutropenia/genética , Neumonía Bacteriana/microbiología , Cordón Umbilical/patología , Vacuna BCG/inmunología , Predisposición Genética a la Enfermedad , Humanos , Masculino , Neutropenia/patología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosaRESUMEN
JAK3 is a tyrosine kinase essential for signaling downstream of the common gamma chain subunit shared by multiple cytokine receptors. JAK3 deficiency results in T-B+NK- severe combined immune deficiency (SCID). We report a patient with SCID due to a novel mutation in the JAK3 JH4 domain. The function of the JH4 domain remains unknown. This is the first report of a missense mutation in the JAK3 JH4 domain, thereby demonstrating the importance of the JH4 domain of JAK3 in host immunity.
Asunto(s)
Janus Quinasa 3/metabolismo , Osteomielitis/genética , Inmunodeficiencia Combinada Grave/genética , Columna Vertebral/patología , Resultado Fatal , Femenino , Humanos , Lactante , Janus Quinasa 3/genética , Mutación , Osteomielitis/complicaciones , Dominios Proteicos , Inmunodeficiencia Combinada Grave/complicaciones , Inmunodeficiencia Combinada Grave/patologíaAsunto(s)
Anomalías Múltiples/diagnóstico , Anomalías Múltiples/genética , Mutación , Nucleotidiltransferasas/genética , Anomalías Múltiples/inmunología , Agammaglobulinemia/diagnóstico , Anemia Sideroblástica/diagnóstico , Linfocitos B/inmunología , Linfocitos B/patología , Cardiomiopatía Hipertrófica/diagnóstico , Discapacidades del Desarrollo/diagnóstico , Homocigoto , Humanos , Lactante , Infecciones/diagnóstico , Masculino , Linaje , Recurrencia , Linfocitos T/inmunología , Linfocitos T/patología , Secuenciación del Exoma/métodosRESUMEN
Primary immunodeficiencies (PIDs) are genetic disorders impairing host immunity, leading to life-threatening infections, autoimmunity, and/or malignancies. Genomic technologies have been critical for expediting the discovery of novel genetic defects underlying PIDs, expanding our knowledge of the complex clinical phenotypes associated with PIDs, and in shifting paradigms of PID pathogenesis. Once considered Mendelian, monogenic, and completely penetrant disorders, genomic studies have redefined PIDs as a heterogeneous group of diseases found in the global population that may arise through multigenic defects, non-germline transmission, and with variable penetrance. This review examines the uses of next-generation DNA sequencing (NGS) in the diagnosis of PIDs. While whole genome sequencing identifies variants throughout the genome, whole exome sequencing sequences only the protein-coding regions within a genome, and targeted gene panels sequence only a specific cohort of genes. The advantages and limitations of each sequencing approach are compared. The complexities of variant interpretation and variant validation remain the major challenge in wide-spread implementation of these technologies. Lastly, the roles of NGS in newborn screening and precision therapeutics for individuals with PID are also addressed.